Hospitalist Doctors in Tappahannock, VA Accepting Medicare

3 Hospitalist doctors found. Showing 1 - 3

Dr. Shadi Ghadermarzi, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 618 Hospital Rd, Tappahannock, VA 22560 Phone: 804-443-3311

Alexander Oritseretsolaye Ogedegbe, M.D. Hospitalist Medicare: Medicare Enrolled Practice Location: 618 Hospital Rd, Tappahannock, VA 22560 Phone: 804-443-3311    Fax: 804-443-6150

Dr. Mohammed S Abdulghani, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 618 Hospital Rd, Tappahannock, VA 22560 Phone: 804-443-3311    Fax: 804-443-6150

News Archive

Muscle-sparing abdominal flaps can reduce complications in women undergoing breast reconstruction

In women undergoing breast reconstruction using their own (autologous) tissue, newer "muscle-sparing" abdominal flaps can reduce complications while improving some aspects of quality of life, reports a study in the March issue of Plastic and Reconstructive Surgery, the official medical journal of the American Society of Plastic Surgeons.

Health risk behaviors such as smoking and obesity associated with lower prostate specific antigen awareness

According to a study conducted at Columbia University Mailman School of Public Health, health risk behaviors such as smoking and obesity are associated with lower awareness of the Prostate Specific Antigen (PSA), which could lead to a lower likelihood of undergoing actual prostate cancer screening.

Genetic mutation linked to excess risk of lethal prostate cancer in obese patients

Obesity is associated with a worse prostate cancer prognosis among men whose tumors contain a specific genetic mutation, suggest results from a new study led by Harvard School of Public Health, Dana-Farber Cancer Institute and Brigham and Women's Hospital researchers.

Adding drug to presurgery chemotherapy improves results for women with triple-negative breast cancer

The I-SPY 2 trial, an innovative, multidrug, phase II breast cancer trial, has yielded positive results with the first drug to complete testing in the trial. Adding the chemotherapy carboplatin and the molecularly targeted drug veliparib to standard presurgery chemotherapy improved outcomes for women with triple-negative breast cancer, according to results from the I-SPY 2 trial presented here at the 2013 San Antonio Breast Cancer Symposium, held Dec. 10-14.

Read more Medical News

› Verified 5 days ago